"We look forward to reporting further progress over the months ahead," said CEO Olav Hellebo in a statement.
"There are currently no therapeutic interventions available to patients living with disability resulting from acute ischaemic stroke," he said.
"We are therefore excited to be moving closer towards potentially changing this situation with our therapeutic candidate targeting stroke disability."
Hellebo added that, after collecting further feedback from US and European regulatory authorities, ReNeuron expected to be able to commence a Phase III study with its CTX cell therapy candidate in stroke disability in the second half of this year.
At 9:48am: [LON:RENE] ReNeuron Group PLC share price was +0.08p at 2.18p
Story provided by StockMarketWire.com